We investigated potential therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators FTY720 (fingolimod) and selective S1P1 agonist SEW2871 on a spontaneous autoimmune polyneuropathy (SAP) when given orally at 7 mo (anticipated disease onset) for 4 weeks. Clinical severity, electrophysiologic and histological findings were ameliorated in mice treated with 1 mg/kg of FTY720. Subsequent studies showed that SEW2871 was also effective in halting the progression of SAP, which was accompanied by decreased proliferative and cytokine responses to myelin protein zero (P0), and an increase in regulatory T cells. We conclude that S1P receptor modulators may play a therapeutic role in autoimmune neuropathies.
Introduction
Fingolimod (FTY720) is an oral S1P receptor modulator in phase III clinical trials for the treatment of multiple sclerosis (MS). A decrease in MRI and clinical disease activity was observed in a phase II study of FTY720 in MS (Kappos et al., 2006) . FTY720 is highly efficacious in the MS model of experimental autoimmune encephalomyelitis (EAE) (Balatoni et al., 2007; Fujino et al., 2003; Webb et al., 2004) . The beneficial effect of FTY720 in EAE is attributed to lymphocyte sequestration in secondary lymphoid organs, although it also enhances the expression of neuroregenerative genes in the CNS (Chiba et al., 1998; Foster et al., 2008; Graler and Goetzl, 2004; Mandala et al., 2002; Pinschewer et al., 2000) . In addition, dynamic effects of FTY720 and related compounds in oligodendroglial lineage cells have been demonstrated (Coelho et al., 2007; Jaillard et al., 2005; Jung et al., 2007; Miron et al., 2008) .
Not all treatments effective in MS also work consistently for autoimmune neuropathies such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). For example, interferon beta (IFN-β) while effective in MS, has had contradictory outcome in CIDP (Hadden et al., 1999; Vallat et al., 2003) . There is one report describing the beneficial effect of FTY720 (intraperitoneal injection) in P2-induced experimental allergic neuritis (EAN) in Lewis rats (Zhang et al., 2008) . FTY720 is converted in vivo to FTY720-phosphate (FTY720P), which is a potent agonist of four of the five known S1P receptors (S1P1, S1P3, S1P4 and S1P5) (Brinkmann et al., 2002) . It is unclear whether selective S1P1 modulators such as SEW2871 will have a similar therapeutic effect as FTY720 on EAN or EAE. T lymphocyte migration towards S1P gradient is highly dependent on S1P1 receptors, whereas dendritic cell migration is mediated primarily by S1P3 receptors (Allende et al., 2004; Maeda et al., 2007; Matloubian et al., 2004) .
The goal of this study is to investigate whether FTY720 and selective S1P1 agonist SEW2871 exert a therapeutic effect in a model of spontaneous autoimmune polyneuropathy (SAP), the B7-2 knockout (KO) non-obese diabetic (NOD) mice. NOD mice are susceptible to the development of autoimmune diseases such as type 1 diabetes, thyroiditis, sialitis, or neuropathy, but disease manifestations are strongly influenced by co-stimulatory molecules and cytokine milieu (Salomon et al., 2001; Setoguchi et al., 2005) . Elimination of a costimulatory molecule B7-2 in female NOD mice prevents type 1 diabetes and sialitis, but triggers the development of limb weakness at 6-7 mo, which progresses to quadriparesis by 8-9 mo. The incidence of neuropathy is lower in males compared to female B7-2 KO NOD mice. Unlike EAN, SAP mice do not undergo spontaneous recovery. Similar to human CIDP, electrophysiological findings in SAP are classical for a demyelinating process with superimposed axonal loss. 
